HMGB1 is related to disease activity in children with celiac disease

• Published in: Clinics and research in hepatology and gastroenterology Vol. 47; no. 7; p. 102175
• Main Authors: Yagci, Murat, Aydemir, Yusuf, Baris, Zeren
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.08.2023
• Subjects: Celiac disease; High mobility gene box-1; Inflammation; Celiac disease; Inflammation; High mobility gene box-1
• ISSN: 2210-7401; 2210-741X
• DOI: 10.1016/j.clinre.2023.102175

•The HMGB1 level was significantly higher in celiac patients compared to healthy controls and patients in remission.•The HMGB-1 reflects the severity of mucosal atrophy at the time of diagnosis in celiac patients.•The HMGB-1 could be used to show remission in the follow-up. We aim to evaluate of the relationship between high mobility gene box-1 (HMGB1) levels and clinical, laboratory and histopathological findings at diagnosis and in remission in children with Celiac Disease (CD). The study included 36 celiac patients at diagnosis, 36 celiac patients in remission, and 36 healthy controls. Patients with intestinal pathologies other than CD, and accompanying inflammatory and/or autoimmune diseases were excluded. Relationship between HMGB1 levels and clinical, laboratory and histopathological findings were evaluated. A total of 72 celiac patients [36 (18 girls, 18 boys, mean age 9.41±3.9 years) in group 1 and 36 (18 girls, 18 boys, mean age 9.91±3.36 years) in group 2] and 36 healthy controls in group 3 (19 girls, 17 boys, mean age 9.56±4 years) were included. The HMGB1 level was significantly higher in group 1 compared to group 2 and group 3 [36.63 (17.98–54.72) ng/ml vs 20.31 (16.89–29.79) ng/ml, p = 0.028 and 36.63 (17.98–54.72) ng/ml vs 20.38 (17.54–24.53) ng/ml p = 0.012, respectively]. A serum HMGB-1 level of 26.553 ng/ml was found to be a cut-off value for the CD with 61% sensitivity, 83% specificity, 78% positive predictive value, and 68% negative predictive value. Higher HMGB1 values were seen in patients with intestinal findings, anemia, anti-tissue transglutaminase IgA levels that were greater than 10 times upper limit of normal, and patients with a higher degree of atrophy as classified by Marsh-Oberhuber. In conclusion, it was thought that HMGB-1 might be a marker that reflects the severity of atrophy at the time of diagnosis and could be used to control dietary compliance in the follow-up. However, there is need for larger population studies in order to evaluate its value as a serological marker for the diagnosis and follow-up of CD and to find a more reliable cut-off value.